ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Survival and patterns of recurrence in patients with nasopharyngeal carcinoma from a non-endemic region-A German multicenter analysis.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine oncological outcomes and patterns of recurrence of nasopharyngeal carcinoma (NPC) in a non-endemic population.
methodsMERLIN (DRKS00034782) is a retrospective study initiated by the Young DEGRO that included NPC patients who received definitive radiotherapy between 2004 and 2023. Overall survival (OS) and disease-free survival (DFS) were determined using Kaplan-Meier analyses, while the incidence of treatment failures was analyzed with death as a competing event. Prognostic variables were identified using Cox regression analyses.
resultsTwo hundred ninety-nine patients from 9 centers were analyzed; 274 (92%) were treated with concurrent systemic treatment, while 48 (16%) and 14 (5%) received induction and adjuvant chemotherapy. After a median follow-up of 62 months, 93 deaths, 40 local failures (LF), 19 regional failures (RF), and 41 distant failures (DF) were observed. Most LF (30/40), RF (15/19), and DF (38/41) occurred within the first 3 years after treatment. Five-year OS and DFS rates were 71% and 61%, while the 5‑year incidences of locoregional failures (LRF) and DF were 18% and 14%. In the multivariable analysis, age (HR, 1.03; 95% CI, 1.01-1.05), Karnofsky performance status (≤ 80% vs. ≥ 90%; HR, 1.97; 95%CI, 1.27-3.07), and AJCC/UICC stage (IV vs. I‑III; HR, 2.18; 95%CI, 1.42-3.35) were associated with DFS.
conclusionThe rates of LRF and DF in this cohort are similar, and the highest risk for disease progression is within the first 3 years after treatment. Future analyses are needed to assess potential improvements with the use of induction and adjuvant systemic therapy.
Indexed as
Identifiers
42606551What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.